BUDAPEST, Hungary, Feb. 21, 2025 /PRNewswire/ -- On February 21, 2025, Zoomlion Heavy Industry Science & Technology Co., Ltd. ("Zoomlion") announced its plan to establish a modern smart factory for aerial work platforms in Hungary. The project, formalized through an agreement signed on Feb. 20, was highlighted at a press conference hosted by the Minister of Foreign Affairs and Trade of Hungary.

Strategically located in Tatabánya at the intersection of major highway networks, the factory will serve as a vital hub linking Eastern and Western Europe's key logistics routes. Once operational, it is expected to significantly strengthen Zoomlion's presence in the European aerial work platform sector.

With a total area of approximately 250 mu (approximately 41.18 acres), the factory will be jointly developed by Zoomlion and CTP Group. The facility will be equipped with advanced intelligent, digital, and environmentally sustainable production technologies to manufacture a wide range of high-performance, premium-quality, and low-carbon aerial work platforms. By leveraging cutting-edge production processes and equipment, the facility will be better positioned to serve both local and European markets.

Once operational, the project is expected to create 800 local job opportunities, fostering economic growth and employment in the region. It will also strengthen collaboration with local supply chain partners, enhance synergy with local businesses, and actively cultivate a localized industrial ecosystem through a closely integrated, mutually beneficial partnership, further contributing to Hungary's economic and social development.

In recent years, Zoomlion has been actively advancing its global business strategy through a "global village" mindset and a localized operational approach. The company has established 10 overseas R&D and manufacturing bases, with products sold in over 150 countries and regions. More than 50% of Zoomlion's revenue now comes from markets outside China.

"We'd like to extend our sincere gratitude to all parties who have supported this project," stated Zhan Chunxin, Chairman and CEO of Zoomlion. "We will accelerate project implementation according to the investment strategy, and bring the factory into operation in this year."

Stars Qin Li, Dylan Wang, Tao Yin, RuoYun Zhang to Attend

SINGAPORE, Feb. 21, 2025 /PRNewswire/ -- On February 28, 2025, the "2024 Yuewen Global IP Awards" will take place at Resorts World Sentosa in Singapore. The event will feature diverse programs including the release of the annual IP honor list, captivating stage performances, a star-studded red-carpet show, and an insightful industry forum. It aims to build a platform to promote IP industry integration and serve as a gateway for Chinese IPs to expand internationally.

The event will attract a total of over 3,000 industry luminaries, cultural icons, and IP fans worldwide. Notable attendees include over 100 globally renowned online literature authors with cumulative hundreds of millions of fans, such as Cuttlefish That Loves Diving, Er Gen, Paperboy, The Speaking Pork Trotter, Qian Shan Cha Ke, Tian Xia Gui Yuan, Aoki_Aku, Guiltythree, and JKSManga. For instance, Cuttlefish That Loves Diving's works Lord of Mysteries and Circle of Inevitability have amassed over 40 million global readers. Meanwhile, IP adaptations like Guardians of the Dafeng (based on Paperboy's web novel), The Double (based on Qian Shan Cha Ke's web novel), and Blossom (based on Zhi Zhi's web novel) have dominated 2024's hit drama rankings.

Adding to the glamour, film and TV stars including XiaoWei Duan, Qin Li, Gang Wu, Dylan Wang, RunZe Wang, Ava Wang, Kiki Xu, Tao Yin, RuoYun Zhang, and Zhu Zhu, alongside music artists Loger, Mario, Laure Shang, Azora Chin, Angela Zhang, will grace the event (Names arranged in alphabetical order from A - Z based on their family names). They will join representatives from China and Singapore's IP sectors, industry associations, academia, and IP industry partners to celebrate the rise of China's IP ecosystem.

A highlight of the evening will be the unveiling of Yuewen's highly anticipated annual IP honor list, which includes but is not limited to Influential Novels of the Year, Most Anticipated Adaptations, Outstanding Author of the Year, and Actor of the Year. The awards spotlight 2024's top-performing IPs across literature, animation, film, TV, gaming, and merchandise, showcasing Chinese cultural and entertainment industry achievements in 2024.

First launched in 2015, the awards have evolved into a "bellwether of Chinese IP development" renowned for their authority and influence. Notably, all past award-winning works have initiated or completed IP adaptation, spanning publishing, audiobooks, comics and animation, TV dramas and films, gaming, and merchandise. Over 70% of these IPs have achieved international success. For example, Joy of Life 2 (winner of "Most Anticipated Adaptations" last year) broke viewership records on Tencent Video and became the most-watched Chinese series on Disney+ in 2024. Other hits like Guardians of the Dafeng, The Legend of ShenLi, The Outcast, and Tales of Herding Gods have dominated various markets, validating the list's industry impact.

In 2024, China's "Goods Economy" (the booming IP-derived merchandise market) surged to 168.9 billion yuan, marking a 40% year-on-year increase and entering a golden growth phase. Projections suggest the market will exceed 308.9 billion yuan by 2029. In keeping with this trend, the "2024 Yuewen Global IP Awards" will debut new award categories for IP merchandise and IP cross - brand marketing, accelerating synergy between the IP and retail economies.

Historically, many of the entertainment industry's most iconic works, ranging from classics such as Gone with the Wind and The Godfather to more contemporary sensations like Harry Potter, The Lord of the Rings, and House of Cards, originated from novels. The publishing landscape has undergone a drastic evolution. Chinese companies, with Yuewen serving as a prime example, are now tapping into the potential of digital publishing platforms, web novels, and their authors for comprehensive IP development. These elements offer a rich trove of high-quality content, complete with built - in, passionate fan bases, presenting a valuable new resource for the entertainment industry.

The "2024 Yuewen Global IP Awards" will be live-streamed on WeTV at 6 p.m. on February 28, 2025.

About Yuewen

Yuewen (HKEX: 0772 China Literature Limited) is a culture and entertainment group that was founded in March 2015. It focuses on creating and developing intellectual property (IP) derived from online literature. Yuewen has a diverse portfolio of well-known brands, such as QQ Reading, Qidian, New Classics Media, and Tencent Animation & Comics. It serves as a platform for tens of millions of creators and a rich reserve of literary works across 200 genres, catering to hundreds of millions of users. Yuewen is renowned for its celebrated IP portfolio, which includes popular titles like Joy of Life, My Heroic Husband, Candle in the Tomb, The King's Avatar, Soul Land, and Nirvana in Fire. It has successfully expanded its reach across various media formats, including audiobooks, animation, comics, films, drama series, games, and offline merchandise.

For more information, please visit https://www.yuewen.com/en/.

- Earnings Conference Call to be Held on Tuesday, March 18, 2025
at 8:00 pm (Hong Kong Time) / 8:00 am (U.S. Eastern Time)

HONG KONG, Feb. 21, 2025 /PRNewswire/ -- China Literature Limited ("China Literature" or "the Company", 0772.HK), a leading online literature and intellectual property ("IP") incubation platform in China, will announce its financial results for the full year of 2024 on Tuesday, March 18, 2025.

China Literature's management team will host a conference call to present an overview of the Company's financial performance and business operations. A live webcast of the call can be accessed on the Company's investor relations website at http://ir.yuewen.com.

Details of the conference call and webcast are as follows:

For participants who wish to join the conference using dial-in numbers, please register in advance using the link provided below and dial in 10 minutes prior to the call. Your dial-in numbers, passcode and unique access PIN would be provided upon registering.

Contact

業績電話會議將於2025年3月18日星期二

晚上8:00（香港時間）/ 上午8:00（美國東部時間）舉行

香港2025年2月21日  /美通社/ -- 中國領先的在線閱讀和IP培育平台閱文集團（「閱文」或「公司」，股份代號：0772.HK）宣佈將於2025年3月18日星期二公佈2024年全年業績。

閱文集團管理層將召開電話會議，討論期內公司財務和業務狀況。電話會議的網絡直播可在公司投資者關係網站http://ir.yuewen.com同步收聽。

電話會議和網絡直播詳情如下：

如與會者希望使用電話號碼撥入會議，請使用下面提供的鏈接提前註冊，並在會議開始前10分鐘撥入。您的撥打號碼，密碼和唯一的訪問PIN碼將會在註冊時提供。

如有垂詢，敬請聯絡：

HONG KONG and SHANGHAI, Feb. 21, 2025 /PRNewswire/ -- Fosun's global operations achieved another milestone. On February 20, during the Abu Dhabi Investment Forum in Shanghai, Fosun International signed a Memorandum of Strategic Cooperation with the Abu Dhabi Investment Office (ADIO). This collaboration aims to drive the expansion of Fosun's subsidiaries into Abu Dhabi and the broader Middle East region, injecting fresh momentum into Fosun's global presence and industrial operations.

Under the agreement, ADIO will provide Fosun with tailored investment support, streamlined market access, and strategic resource connections. These efforts will support Fosun's development in Abu Dhabi's key growth sectors, including healthcare innovation, wealth management, fintech, tourism and Hive City projects. Together, ADIO and Fosun aim to further amplify Fosun's influence across the Middle East.

ADIO enables investors to establish and grow their businesses in the region. It supports market leaders in expanding globally from Abu Dhabi, providing access to a strong partner network and interconnected economic clusters. With tailored guidance and resources, ADIO contributes to sustainable growth and long-term investment in the emirate's dynamic economy.

H.E. Badr Al-Olama, Director General of ADIO, said: "Abu Dhabi continues to attract the world's most prestigious companies, reinforcing the emirate's standing as a globally attractive investment destination. Partnering with Fosun International underscores our commitment to promoting high-impact investments that drive innovation and accelerate Abu Dhabi's economic transformation. As one of China's most reputable conglomerates, Fosun's entry into Abu Dhabi will open new avenues of collaboration across diverse industries, further advancing the emirate's vision of robust sustainable economic growth."

According to the agreement, Fosun will collaborate with ADIO to enhance Abu Dhabi's efforts to attract global investors and family offices, in addition to supporting the development of ADIO's economic clusters.

In addition, Fosun's key members in the financial and technology sectors—Fosun Wealth Holdings and Finloop—are actively engaging with relevant institutions in the Middle East to explore cooperation opportunities in wealth management and fintech. These efforts aim to further support Abu Dhabi in building a world-class investment ecosystem.

Wilson Jin, Senior Vice President of Fosun International, commented: "Abu Dhabi's strategic location, business-friendly environment and world-class regulatory framework make it the ideal hub for Fosun's next phase of international growth and scaling our subsidiaries. The partnership with ADIO will allow us to expand our footprint, attract top-tier investors and contribute to the emirate's economic vision."

Strengthening Presence in the Middle East: Fosun's Recent Developments

After more than 30 years of development, Fosun has grown into a benchmark for Chinese private enterprises in global operations. With operations in more than 35 countries and regions, Fosun's industrial ecosystem increasingly demonstrates its synergistic advantages. Under the new economic landscape, Fosun continues to advance its globalization efforts. The Middle East, with its economic vitality and high-growth potential, is gradually becoming a key frontier in Fosun's global operation strategy.

In December 2024, Hainan Mining's wholly-owned subsidiary, Roc Oil, successfully completed the full offer for Tethys Oil AB, acquiring its multiple oilfield blocks in Oman. This transaction not only marks the continued advancement of the company's internationalization strategy, expanding its business operations into the Middle East and enhancing its global operational capabilities, but also provides broader opportunities for future growth.

In November 2024, Fosun Pharma's innovative biopharmaceutical subsidiary, Henlius entered into a strategic collaboration with AL-TIRYAQ AL-KHALAWI Medical Company ("SVAX"). The two parties will establish joint ventures in Saudi Arabia to integrate Henlius' leading capabilities in the research, development, and manufacturing of biologics with SVAX's local expertise in registration, market access, and commercialization. The collaboration seeks to advance the global registration and commercialization of multiple Henlius products and enhance the accessibility of advanced biologics across the Middle East, North Africa, and Türkiye (MENAT) countries, and benefit more patients. In June last year, Henlius' independently developed and produced product, Hanquyou® was successfully shipped to Saudi Arabia, marking the first domestically produced monoclonal antibody biologic drug to enter the Middle Eastern market.

FFT, a global leader in flexible automation production line solutions under Fosun, signed a joint venture agreement with Saudi family business Khaled Juffali Company (KJC) in July 2024. The plan is to establish a commercial technology entity in Saudi Arabia, and collaborate with Shanghai Easun Technology, FFT's parent company under Fosun, to provide automated production line solutions for Saudi Arabia's electric vehicle industry. The joint venture has already secured its first project in Saudi Arabia's automotive sector.

In just six months, Fosun has achieved successive breakthroughs in the Middle East market, spanning multiple sectors including healthcare, energy, finance, and intelligent manufacturing. This string of achievements not only stems from Fosun's unwavering execution of its "globalization" strategy but also demonstrates Fosun's excellent operational capabilities and strong advantages in resource integration. Meanwhile, Fosun's rich experience in the Chinese market and its diversified, synergistic industrial ecosystem have shown Middle Eastern partners the enormous potential for collaboration and shared success.

Fosun International Chairman, Guo Guangchang, stated: "Fosun looks forward to establishing long-term and stable strategic cooperation with more Middle Eastern partners. As a company with global operational capabilities and deep roots in the Chinese market, I believe Fosun is the best strategic partner. With our global operational capabilities and extensive experience, Fosun can achieve sustainable value growth with Middle Eastern partners and create a new win-win ecosystem. "

香港和上海2025年2月21日 /美通社/ -- 復星全球化運營再傳利好消息：2月20日，在上海舉行的阿布扎比投資論壇上，復星國際與阿布扎比投資辦公室（Abu Dhabi Investment Office，即ADIO）簽署戰略合作備忘錄，旨在推動復星旗下子公司擴展至阿布扎比及更廣泛的中東地區，為復星全球化佈局和產業運營注入新動力。

根據協議，ADIO將為復星提供定制化的投資支持、便捷的市場准入以及戰略性資源對接，助力復星在阿布扎比關鍵增長領域的佈局，包括醫療健康創新、財富管理、金融科技、旅遊與蜂巢等，並攜手復星進一步擴大其在中東地區影響力。

阿布扎比投資辦公室致力於助力全球投資者在區域內建立和發展相關業務。該機構支持行業領導者從阿布扎比走向全球，並為其提供強大的合作夥伴網絡和接觸相互連接的經濟集群機會。憑藉定制化指引和資源導入能力，ADIO為酋長國經濟發展中的可持續增長和長期投資做出了貢獻。

阿布扎比投資辦公室總幹事巴德爾•阿爾-奧拉馬對此次合作表示高度認可：「阿布扎比持續吸引著來自世界各地最具聲望的企業，鞏固了其作為全球備受矚目的投資目的地的地位。此次與復星國際合作，充分體現了我們致力於推動高價值投資、加速創新和實現阿布扎比經濟轉型的承諾。作為中國最具影響力的企業之一，復星的入駐將為多個行業開啟全新的合作機會，此舉也將進一步推進酋長國加速可持續經濟增長的願景。」

復星還將與ADIO合作，助力阿布扎比吸引全球投資者和家族辦公室，推動 ADIO 經濟集群的進一步發展。

據悉，復星旗下金融與科技領域的核心成員——復星財富控股（Fosun Wealth Holdings）和星路科技（Finloop）正與中東相關機構積極接洽，探索在財富管理和金融科技等領域的合作機會，進一步助力阿布扎比打造國際化的投資生態體系。

復星國際高級副總裁金華龍表示：「阿布扎比的戰略地理位置、友好的營商環境以及世界領先的監管體系，使其成為復星下一階段國際化發展及子公司擴張的理想樞紐。此次合作將助力我們拓展全球業務版圖，吸引頂級投資者，並為阿布扎比的經濟願景貢獻力量。」

強化中東市場佈局，復星動作頻頻

經過30多年的發展，復星已成長為中國民營企業全球化運營的標杆，在全球逾35個國家和地區開展業務，產業生態的協同效應日趨明顯。在新的經濟形勢下，復星全球化步伐不停，中東地區憑藉其經濟活力和高增長潛力，正逐漸成為復星全球佈局的重要前沿。

2024年12月底，海南礦業全資子公司洛克石油完成對特提斯石油公司（Tethys Oil AB）的全面要約收購，獲取其在阿曼多個區塊的油田權益。這一交易不僅標誌著公司國際化戰略的持續推進，將業務板塊拓展至中東，提升國際化運營能力，還為未來發展提供了更廣闊的空間。

2024年11月，復星醫藥旗下創新生物製藥企業復宏漢霖與沙特阿拉伯知名醫療保健公司AL-TIRYAQ AL-KHALAWI Medical Company（簡稱「SVAX」）達成戰略合作。雙方將於沙特阿拉伯設立合資公司，整合漢霖領先的生物藥研發及生產能力與SVAX的本地註冊、市場准入和商業化優勢資源，推動復宏漢霖多款產品的全球註冊與商業化，共同提升先進生物藥在中東北非土耳其地區（MENAT）的可及性，惠及更多患者。同年6月，復宏漢霖自主研發和生產的漢曲優^®成功發貨沙特，成為首個登陸中東市場的國產單抗生物藥。

2024年7月，復星旗下全球領先的柔性自動化生產線解決方案供應商FFT與沙特家族企業Khaled Juffali Holding Company（KJC）簽署合資協議，計劃在沙特建立商業技術實體，並與FFT股東上海翌耀科技合作，為沙特電動車行業提供自動化生產線解決方案。目前，該合資企業已獲得沙特汽車行業的首個項目。 

短短半年時間，復星接連在中東市場取得突破，涵蓋醫藥、能源、金融、智能製造等多個領域。這一連串成果不僅得益於復星對「全球化」戰略的堅定執行，更體現了復星卓越的運營能力及強大的資源整合優勢。同時，復星對中國市場的豐富經驗及其構建的相互賦能的多元產業，也讓中東合作夥伴看到了攜手共贏的巨大潛力。

復星國際董事長郭廣昌此前表示：「復星期待與更多的中東夥伴建立長期穩定的戰略合作。作為一家具備全球運營能力並深耕中國市場的企業，我相信復星是最佳的戰略夥伴。憑藉我們全球運營能力和豐富經驗，復星能夠與中東的合作夥伴共同實現持續價值增長，打造互利共贏的新生態圈。」

HONG KONG, Feb. 21, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced the company has successfully enrolled the first patient in its multicenter, randomized, double-blind Phase III clinical trial of ivonescimab in combination with chemotherapy for first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) (HARMONi-BC1/AK112-308). Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody independently developed by the company.

HARMONi-BC1/AK112-308 study is led by Professor Xu Binghe, a renowned breast cancer expert and academician of the Chinese Academy of Engineering, from the Cancer Hospital of the Chinese Academy of Medical Sciences. Preliminary efficacy data presented at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting demonstrated that ivonescimab combined with chemotherapy showed significant therapeutic efficacy and also exhibited a favorable safety profile, underscoring its clinical potential for the treatment of locally advanced or metastatic TNBC.

Akeso has strategically positioned ivonescimab within a comprehensive development plan, aiming to reshape the landscape of cancer immunotherapy and establish a new global standard of care. Ivonescimab, in combination with chemotherapy, has been approved in China for the treatment of EGFR-TKI-resistant, non-squamous NSCLC. The New Drug Application (sNDA) for ivonescimab monotherapy as a first-line treatment for PD-L1-positive NSCLC (in comparison to pembrolizumab) is currently under review and has been granted priority status in China.

Three international multicenter Phase III clinical trials, led by our partner Summit Therapeutics, are progressing efficiently or are being initiated:

• The HARMONi study, an international multicenter Phase III clinical trial evaluating ivonescimab in combination with chemotherapy for non-squamous NSCLC with progression after third-generation EGFR-TKI treatment, has had patient enrollment completed and has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA),
• The HARMONi-3 study, an international multicenter Phase III clinical trial comparing ivonescimab combined with chemotherapy as first-line treatment for both squamous and non-squamous NSCLC (versus pembrolizumab combined with chemotherapy),
• The HARMONi-7 study, an international multicenter Phase III clinical trial evaluating ivonescimab monotherapy as first-line treatment for PD-L1 high-expressing NSCLC (versus pembrolizumab).

Several Phase III clinical trials are progressing efficiently or are being initiated in China, including:

• Ivonescimab combined with chemotherapy as first-line treatment for squamous NSCLC (vs. tislelizumab combined with chemotherapy, HARMONi-6/AK112-306),
• Ivonescimab combined with chemotherapy as first-line treatment for biliary tract cancer (vs. durvalumab combined with chemotherapy, HARMONi-GI1/AK112-309),
• Ivonescimab combined with AK117 (CD47) as first-line treatment for PD-L1 positive head and neck squamous cell carcinoma (vs. pembrolizumab, SOLO-10/AK117-302),
• First-line treatment for pancreatic cancer (HARMONi-GI2/AK112-310),
• First-line treatment for triple-negative breast cancer (HARMONi-BC1/AK112-308).

About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 22 candidates have entered clinical trials (including 11 bispecific/multispecific antibodies and bispecific antibody-drug conjugates). Additionally, 5 new drugs are commercially available, and 5 new drugs across 7 indications are currently under regulatory review for approval. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin, and X (formerly Twitter).

HONG KONG, Feb. 21, 2025 /PRNewswire/ -- CNOOC Limited (the "Company", SEHK: 00883 (HKD Counter) and 80883 (RMB Counter), SSE: 600938) today announces that Luda 5-2 North Oilfield Phase II Development Project has commenced production.

The project is located in the central part of the Bohai Sea, with an average water depth of approximately 30 meters. The main production facilities include 1 new auxiliary production platform and 1 production wellhead platform. A total of 29 development wells are planned to be commissioned, including 28 production wells and 1 water source well. The project is expected to achieve a peak production of approximately 6,700 barrels of oil equivalent per day in 2026. The oil property is heavy crude.

Luda 5-2 North Oilfield is the first oilfield to produce from super heavy oil reservoirs through thermal recovery in China. Its Phase I Project had already commenced production in 2022. CNOOC Limited made major technological breakthroughs in this project and significantly enhanced the development efficiency of offshore super heavy oil. The Phase II Project will further tap the resources of the oilfield. Through optimized Jet Pump Injection-Production Technology, the project realized efficient and economic development of heavy crude, which could further enhance the Company's energy supply capacity.

CNOOC Limited holds 100% interest in this project and is the operator.

— End —

Notes to Editors:

More information about the Company is available at http://www.cnoocltd.com. 

*** *** *** ***

This press release includes forward looking information, including statements regarding the likely future developments in the business of the Company and its subsidiaries, such as expected future events, business prospects or financial results. The words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify such forward-looking statements. These statements are based on assumptions and analyses made by the Company as of this date in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company currently believes are appropriate under the circumstances. However, whether actual results and developments will meet the current expectations and predictions of the Company is uncertain. Actual results, performance and financial condition may differ materially from the Company's expectations, including but not limited to those associated with macro-political and economic factors, fluctuations in crude oil and natural gas prices, the highly competitive nature of the oil and natural gas industry, climate change and environmental policies, the Company's price forecast, mergers, acquisitions and divestments activities, HSSE and insurance policies and changes in anti-corruption, anti-fraud, anti-money laundering and corporate governance laws and regulations.

Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements. The Company cannot assure that the results or developments anticipated will be realised or, even if substantially realised, that they will have the expected effect on the Company, its business or operations.

*** *** *** ***

For further enquiries, please contact:

Ms. Cui Liu
Media & Public Relations
CNOOC Limited
Tel: +86-10-8452-6641
Fax: +86-10-8452-1441
E-mail: [email protected] 

Mr. Bunny Lee
Porda Havas International Finance Communications Group
Tel: +852 3150 6707
Fax: +852 3150 6728
E-mail: [email protected]

香港2025年2月21日 /美通社/ -- 中國海洋石油有限公司（「公司」或「中國海油」，香港聯交所股票代碼：00883（港幣櫃台）及80883（人民幣櫃台），上海證券交易所股票代碼：600938）今天宣佈旅大5-2北油田Ⅱ期開發項目已投產。

該項目位於渤海中部海域，平均水深約30米，主要生產設施為新建1座生產輔助附屬平台和1座生產井口平台。計劃投產開發井29口，其中包括生產井28口，水源井1口。預計2026年將實現日產約6,700桶油當量的高峰產量，油品性質為重質原油。

旅大5-2北油田是中國首個特超稠油熱採開發油田，其I期項目已於2022年投產。中國海油在該項目實現了海上稠油熱採的重大技術突破，顯著提升了海上特超稠油開發效率。Ⅱ期項目將進一步挖掘油田儲量潛力，通過優化射流泵注採技術並擴大應用，實現稠油儲量的高效經濟開發，為提高公司能源供應能力做出重要貢獻。

中國海油擁有該項目100%的權益，並擔任作業者。

— 完 —

編者注：

如需瞭解中國海洋石油有限公司更多信息，請登錄公司網站http://www.cnoocltd.com

*** *** *** *** 

本新聞稿包含公司的前瞻性資料，包括關於本公司和其附屬公司業務相當可能有的未來發展的聲明，例如預期未來事件、業務展望或財務結果。「預期」、「預計」、「繼續」、「估計」、「目標」、「持續」、「可能」、「將會」、「預測」、「應當」、「相信」、「計劃」、「旨在」等詞匯以及相似表達意在判定此類前瞻性聲明。這些聲明以本公司在此日期根據其經驗以及對歷史發展趨勢，目前情況以及預期未來發展的理解，以及本公司目前相信的其它合理因素所做出的假設和分析為基礎。然而，實際結果和發展是否能夠達到本公司的目前預期和預測存在不確定性。實際業績、表現和財務狀況可能與本公司的預期產生重大差異，這些因素包括但不限於宏觀政治及經濟因素、原油和天然氣價格波動有關的因素、石油和天然氣行業高競爭性的本質、氣候變化及環保政策因素、公司價格前瞻性判斷、併購剝離活動、HSSE及保險安排、以及反腐敗反舞弊反洗錢和公司治理相關法規變化。

因此，本新聞稿中所做的所有前瞻性聲明均受這些謹慎性聲明的限制。本公司不能保證預期的業績或發展將會實現，或者即便在很大程度上得以實現，本公司也不能保證其將會對本公司、其業務或經營產生預期的效果。

*** *** *** ***

如有進一步查詢，請聯絡：

劉  翠
媒體/公共關係
中國海洋石油有限公司
電話：+86-10-8452-6641
傳真：+86-10-8452-1441
電郵：[email protected] 

李耀榮
博達浩華國際財經傳訊集團
電話: +852 3150 6707
傳真: +852 3150 6728
電郵：[email protected]

The three major US stock indexes tumbled on Thursday amid market concerns about US President Donald Trump's new tariff plan. The DJIA’s slump deepened, with the biggest drop of 677 points, bottoming at 43,950. The downfall eventually narrowed to 450 points or 1%, to rest at 44,176.

The S&P 500, which had set new highs for several consecutive days, ebbed back from its peak, closing 26 points or 0.4% lower at 6,117. The Nasdaq sank 93 points or 0.5% to 19,962.

Walmart (WMT.US) cratered 6.5% after delivering rosy results for the previous fiscal quarter but expecting profit growth to slow.

Techs traded mixed. Tesla (TSLA.US) and Amazon (AMZN.US) fell 1.7% each, whereas Meta (META.US) dropped 1.3%. Nvidia (NVDA.US) gained 0.6%, while Apple (AAPL.US) inched up 0.4%.

Chinese ADRs had a good run, with Alibaba (BABA.US) closing up 8.1% after reporting quarterly results beat. Bilibili (BILI.US) also surged 8.8%, while JD.com (JD.US) shot up 5%.
~



AAStocks Financial News
Web Site: www.aastocks.com